Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens*
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Practical hormonal male contraceptive regimens are likely to have delayed onset and offset of reliable contraception dictated by the length of the spermatogenic cycle and clearance rate of pre-formed sperm from the ductular system. While delayed onset of contraceptive efficacy is an accepted feature of vasectomy, reliable time estimates for a hormonal male contraceptive of time to onset and offset of reliable contraception and of resumption of normal male fertility are required. METHODS AND RESULTS: We utilized the sperm output data from three male contraceptive efficacy studies to define quantitative estimates of suppression and recovery rates from an androgen alone (testosterone enanthate) and an androgen/progestin (testosterone/depot medroxyprogesterone acetate) study. Using nearly 14,000 semen samples from World Health Organization (WHO) studies #85921 and #89903 with identical protocols, the rate of suppression of sperm output was best modelled as a two-parameter, single exponential decay function with effective half-time to suppression of 5.5 weeks and times of 6.8 weeks to 10 x 10(6)/ml, 8.7 weeks to 5 x 10(6)/ml, 10.0 weeks to 3 x 10(6)/ml and 13.0 weeks to 1 x 10(6)/ml. The rate of recovery using absolute sperm concentration was best modelled as a three-parameter, sigmoidal curve with effective time to reach half of the recovery plateau of 10.5 weeks and times of 9.0 weeks to 3 x 10(6)/ml, 9.9 weeks to 5 x 10(6)/ml, 11.5 weeks to 10 x 10(6)/ml, and 13.6 weeks to 20 x 10(6)/ml. Using relative sperm output, defined as a percentage of the participants' own baseline, recovery approached an asymptotic plateau of approximately 85% of geometric mean pre-treatment sperm concentration. In the combination androgen/progestin study, suppression rate was significantly faster (effective time to reach half maximal suppression of 3.0 weeks) and recovery significantly slower (effective time to reach half of recovery plateau of 14.7 weeks) and less complete (asymptotic recovery plateau of 43% of baseline) than in the androgen-alone WHO studies. CONCLUSION: These findings therefore provide large sample estimates of the suppression and recovery rates from an androgen-alone hormonal male contraceptive regimen as a basis for comparison with other second-generation combination androgen/progestin regimens that are the most promising approach to developing practical male hormonal regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperm Morphology, Motility, and Concentration in Fertile and Infertile Men
Guzick, D. S., Overstreet, J. W., Factor-Litvak, P., Brazil, C. K., Nakajima, S. T., Coutifaris, C., Carson, S. A., Cisneros, P., Steinkampf, M. P., Hill, J. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003005 · Cited by 1,336
Statistic Notes: Regression towards the mean
Bland, J. M., & Altman, D. G. (1994) · BMJ · doi:10.1136/bmj.308.6942.1499 · Cited by 547
High frequency of sub-optimal semen quality in an unselected population of young men
Andersen, A. G. (2000) · Human Reproduction · doi:10.1093/humrep/15.2.366 · Cited by 323 · cited 1×
“…on oracular wisdom rather than empirical evidence and, in the absence of conclusive evidence, it is claimed that this level is too low (Bonde et al., 1998; Zinaman et al., 2000) or too high (Handelsman, 1997; Lemcke et al., 1997; Ombelet et al., 1997; Chia et al., 1998; Andersen et al., 2000).”
Background
Cited by
Eisenberg, M. L., Esteves, S. C., Lamb, D. J., Hotaling, J. M., Giwercman, A., Hwang, K., & Cheng, Y.-S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00459-w · Cited by 536
The impact of drugs on male fertility: a review
Semet, M., Paci, M., Saïas‐Magnan, J., Metzler‐Guillemain, C., Boissier, R., Lejeune, H., & Perrin, J. (2017) · Andrology · doi:10.1111/andr.12366 · Cited by 344
Multicenter Contraceptive Efficacy Trial of Injectable Testosterone Undecanoate in Chinese Men
Gu, Y., Liang, X., Wu, W., Liu, M., Song, S., Cheng, L., Bo, L., Xiong, C., Wang, X., Liu, X., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1846 · Cited by 233
“The incomplete recovery of sperm output in two participants at the 18th month of the recovery follow-up visit may be attributable to regression to the mean (25) in one participant with a sperm concentration of 13 10(6)/ml and intercurrent epididymal infection in another participant with recently acquired, painful epid…”
BackgroundResultLiu, P. Y., Swerdloff, R. S., Anawalt, B. D., Anderson, R. A., Bremner, W. J., Elliesen, J., Gu, Y.-Q., Kersemaekers, W. M., McLachlan, R. I., Meriggiola, M. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2768 · Cited by 126
“Previous work has implicated Asian (compared with Caucasian) ethnicity (19), lower baseline FSH concentration and greater gonadotropin suppression (4, 20), progestin coadministration (21, 22), and lower testosterone dose (22, 23) in more complete eventual suppression of sperm output.”
BackgroundSelf-citationThe Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use
Wenker, E. P., Dupree, J. M., Langille, G. M., Kovac, J., Ramasamy, R., Lamb, D., Mills, J. N., & Lipshultz, L. I. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12890 · Cited by 101
Song, S.-H., Sung, S., Her, Y. S., Oh, M., Shin, D. H., Lee, J., Baek, J., Lee, W. S., & Kim, D. S. (2019) · Clinical and Experimental Reproductive Medicine · doi:10.5653/cerm.2019.00290 · Cited by 14
“cause of this effect, some researchers consider testosterone to be a potentially promising contraceptive [13].”
Background
Metadata
- Authors
- Ly, L. P., Liu, P. Y., & Handelsman, D. J.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-28
- Volume
- 20
- Issue
- 6
- Pages
- 1733-1740
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2020319322
- Cited by
- 49
- References
- 3
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.